Latest Breaking News On - Dmitriy grachev - Page 1 : comparemela.com

Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy. | March 29, 2023

Dmitriy grachevAmanda mooreJoe vazzanoMadhav vasanthavadaAbeona therapeutics incHead of program leadershipCorporate communications abeona therapeuticsExchange commissionBristol myers squibbProgram leadershipInternational societies for investigative dermatologyBusiness developmentSecurities exchangeDrug administrationStargardt diseaseX linked retinoschisis